Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from Type 1 diabetes

TJ McDonald, K Colclough, R Brown, B Shields, M Shepherd, PJ Bingley, AJK Williams, AT Hattersley, S Ellard

Research output: Contribution to journalArticle (Academic Journal)

104 Citations (Scopus)

Abstract

AIM: Maturity-onset diabetes of the young is a monogenic form of familial, young-onset diabetes. It is rare (∼1% diabetes) and may be misdiagnosed as Type 1 diabetes and inappropriately treated with insulin. Type 1 diabetes is characterized by the presence of islet autoantibodies, including glutamate decarboxylase (GAD) and islet antigen-2 (IA-2) antibodies. The prevalence of islet autoantibodies is unknown in maturity-onset diabetes of the young and may have the potential to differentiate this form of diabetes from Type 1 diabetes. The aim of this study was to determine the prevalence of GAD and IA-2 antibodies in patients with maturity-onset diabetes of the young and Type 1 diabetes. METHODS: We measured plasma GAD and IA-2 antibodies in 508 patients with the most common forms of maturity-onset diabetes of the young (GCK: n = 227; HNF1A: n = 229; HNF4A: n = 52) and 98 patients with newly diagnosed Type 1 diabetes (diagnosed <6 months). Autoantibodies were considered positive if ≥ 99th centile of 500 adult control subjects. RESULTS: GAD and/or IA-2 antibodies were present in 80/98 (82%) patients with Type 1 diabetes and 5/508 (<1%) patients with maturity-onset diabetes of the young. In the cohort with Type 1 diabetes, both GAD and IA-2 antibodies were detected in 37.8% of patients, GAD only in 24.5% and IA-2 only in 19.4%. All five patients with maturity-onset diabetes of the young with detectable antibodies had GAD antibodies and none had detectable IA-2 antibodies. CONCLUSION: The prevalence of GAD and IA-2 antibodies in maturity-onset diabetes of the young is the same as in control subjects (<1%). The finding of islet autoantibodies, especially IA-2 antibodies, makes the diagnosis of maturity-onset diabetes of the young very unlikely and genetic testing should only be performed if other clinical characteristics strongly suggest this form of diabetes rather than Type 1 diabetes. This supports routine islet autoantibody testing before proceeding to more expensive molecular genetic testing.
Original languageEnglish
Pages (from-to)1028 - 1033
JournalDiabetic Medicine
Volume28 (9)
DOIs
Publication statusPublished - Sep 2011

Fingerprint Dive into the research topics of 'Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from Type 1 diabetes'. Together they form a unique fingerprint.

  • Cite this

    McDonald, TJ., Colclough, K., Brown, R., Shields, B., Shepherd, M., Bingley, PJ., Williams, AJK., Hattersley, AT., & Ellard, S. (2011). Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from Type 1 diabetes. Diabetic Medicine, 28 (9), 1028 - 1033. https://doi.org/10.1111/j.1464-5491.2011.03287.x